All In Biotech

NDA 202971 · Otsuka Pharm CO LTD

Abilify Maintena Kit

Aripiprazole · Intramuscular

Last checked: Nov 20, 2026Latest source record: Jan 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Feb 28, 2013

Approved uses

5

Original approval plus efficacy supplements

Registered trials

401

123 Phase 3, 18 recruiting

FAERS reports

50,729

40,598 serious, 3,761 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY MAINTENA is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death ( 5.1 ) ABILIFY MAINTENA is not approved for the treatment of patients with dementia-related psychosis ( 5.1 )

What it is approved for

From the label in effect Mar 24, 2026.

ABILIFY MAINTENA (aripiprazole) is indicated: for the treatment of schizophrenia in adults for maintenance monotherapy treatment of bipolar I disorder in adults ABILIFY MAINTENA is an atypical antipsychotic indicated: for treatment of schizophrenia in adults ( 1 ) for maintenance monotherapy treatment of bipolar I disorder in adults ( 1 )

Mechanism: The mechanism of action of aripiprazole in the treatment of schizophrenia and bipolar I disorder is unknown. The efficacy of aripiprazole could be mediated through a combination of partial agonist activity at dopamine D 2 and serotonin 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • ABILIFY MAINTENA KIT · ARIPIPRAZOLE 400MG · FOR SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • ABILIFY MAINTENA KIT · ARIPIPRAZOLE 400MG/VIAL · FOR SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription · TE AP
  • ABILIFY MAINTENA KIT · ARIPIPRAZOLE 300MG · FOR SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • ABILIFY MAINTENA KIT · ARIPIPRAZOLE 300MG/VIAL · FOR SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Aripiprazole" as an intervention, any sponsor and status, largest first.

All 401 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,990
  • off label use3,660
  • product use in unapproved indication3,098
  • weight increased2,709
  • drug interaction2,504
  • anxiety2,166
  • condition aggravated1,873
  • fatigue1,818
  • suicide attempt1,716
  • suicidal ideation1,660
  • psychotic disorder1,642
  • nausea1,627

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200468
2005111
2006161
2007217
2008192
2009256
2010342
2011354
2012534
2013487
2014945
20152,167
20162,091
20173,545
20183,905
20193,887
20203,923
20215,155
20224,387
20234,862
20244,971
20254,466
20263,703

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,035 on PubMed

Sponsor: Otsuka

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.